Aagami, Inc., is an Illinois based life sciences consulting firm offering, 1. Strategic Consulting 2. In / Out Licensing 3. Partnership / Co- development 4. Funding and Investment Advisory 5. Divestiture/ Mergers / Acquisition 6. IP Licensing and Sale 7. Market Entry / Development Strategy In brief, Aagami brings: 1. Deep Experience of overcoming business and socio-cultural differences of various countries/regions 2. Extensive ‘C’ level network nurtured for over 19 years 3. Global Deal making skills, honed for decades 4. Partners having combined experience of 250+ years 5. Supplementing your bandwidth to save time, effort & cost 100+ Bio Pharma clients globally have put their trust in Aagami (150+ assignments) since 2003.

1. → Realizing Possibilities, Together ← April 2022
Strategic Consulting |Global Advisory | Market Intelligence
100+
Clients
150+
Assignments
2020 Calamos Court, Suite 200, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com
30+
Countries

2. In Summary – Aagami, Inc.
Multi-
geographic
presence
Large ‘C’
level
network
20+ deals
100+ Clients
150+
Assignments
Client
Success –
most
important
250+yrs
Global
Experience
Dr. Shridhar Andurkar
Nancy Chew
Dinesh Jain
Michael Rosen
US$ 500+MM
X-Border deals
and Investments
2
Godwyn Francis Dr. Carlos Velez
Strategic Consulting | Lifesciences

3. A life sciences consulting firm offering
For Global companies in
Aagami, Inc.
Strategic Consulting Global Advisory Market Intelligence
Pharma Biotech Medical Devices
Consumer
Healthcare
3

4. Support all stages of
licensing
(Product/IP/Tech)
from Pre-Clinical to
on the Market
Various types of
development
partnering
support
Support in Divestment,
M&A, IP, Techs,
Companies, etc.
To augment your
bandwidth in
regions you are
unable to reach.
In / Out
Licensing
Partnership /
Co-development
Divestiture/
Mergers /
Acquisition
Market Entry /
Development
Strategy
Your Needs, we Serve
Advisory support
for Funding /
Venture Capital
Funding /
Investment
4

5. Deep Experience of overcoming business and socio-cultural
differences of various countries/regions
Extensive ‘C’ level
network nurtured
for 19+ years
Global Deal making
experience of 250+ years
of all Partners combined
Supplementary services of
Market Intelligence and
Business/IP research
Enhancing your
bandwidth for saving
time, effort & cost
Aagami brings,
5

6. Samples of various successes
(More Details in Case Studies)
Co-Development Partnership for
Novel Protein Therapeutic Platform.
2 Deals Done
Management of MSDS through strategic
alliance . 85% Cost reduction achieved
<6 months
Raising Investments for development of
therapies & vaccines. Listing on OTC
Markets using reverse merger, Line of
Credit (US$ 10mn)
Technology Licensing of Dermal
Delivery Platform. 4 Deals signed
with 3 companies for 18 geographies
CONFIDENTIAL
Finding customers for Peptides API
for the Client. Partnered with 8
Companies
CONFIDENTIAL
6
Equity Investment from Large Pharma

7. 7
USA International
Aagami has completed over 150 assignments for more than 100 clients since 2003
Sample list of Clients whom we have served
Japan
India
Netherland
Australia
Ireland
NFL BioSciences
France
UK
Sweden
Germany
S. Korea
Portugal Turkey
Belgium
Israel

8. Representative Client List
8
• Fertigo
• Avisa Myko
• Ingenio Therapeutics
• CMX Twenty
• MedRx
• Neuro42
• Hovione
• PLUS Therapeutics
• Otomagnetics
• Promaxo
• O'Atari
• NFL Biosciences
• 4basecare
• WRS
• Therakind
• Sarva Bio Remed
• Syngulon
• BioLineRx
• CFF
• EuBiologics
• Ethadox
• Quivive
• Mountain View
Pharma
• DS Oil International
• Arstat
• Temple Therapeutics
• Sanovas
• EOS BioSciences
• Avixgen
• SiSaf
• Biose
• Batu Biologics
• JRF Global
• Impel NeuroPharma
• V ClinBio / Cellix Bio
• EmerPharm / NH
Therapeutics
• Galen Pharma
(Almac)
• 22nd Century
• Dispersol
• UniTargetingResearch
• ABL Lipids
• ArjoHuntleigh/ Getinge
• HoneyLab
• iNDx LifeCare
• Venus Remedies
• Opsona Therapeutics
• XL-protein
• Otago (Ubiquitome)
• Oncbiomune
• CreAgri
• Merus
• New Haven Pharma
• Novian
• Laktobiotics
• SOM Biotech SA
• NanoSensing
Technologies
• DesignMedix Inc
• Delmar Pharmaceuticals
• Bugbam
• Pieris AG
• AdvanGene Inc
• Toppan KK
• Affitech A/S
• MacuCLEAR
• Biotechnologies
International
• PLx - Protalix Pharma
• Phosphagenics Ltd (now
Avecho)
• Lifewave LLC
• Natren Inc
• Loyola University Chicago
• Agile Therapeutics
• ScyFIX
• BSV Biosciences
• Penwest Corporation
• Averion International
• Depomed now Assertio
Therapeutics
• Bennu Pharmaceuticals
• Great American Products
• KurveTech
• Genentech
• University of Utah
• Tranzyme
• Solvay
• Epicept Corporation
• Novadel
Pharmaceuticals
• Dow Chemicals
• Aegis Therapeutics
• Morton Grove
Pharmaceuticals
• Advanced Assymetrics
• Interhealth USA
• Focus Synthesis
• Source Management
International
• Bio Quant
• Unitech
Pharmaceuticals
• Eczacibasi
• CCDRD
• Ilsan Ilvac

9. Client Testimonials
9
Virtues include Aagami’s
attentiveness, network, and
integrity. Excellent and will
recommend to all
Aagami is the bridge that
crosses many gaps. Importantly
it does so openly and honestly.
Pleased by Aagami’s
professional and gracious work.
Delighted to recommend to
others
Other Consultants we worked
with in US and Canada do not
even stand in Aagami’s shadow
Founder and CEO of a California based Biopharma
Founder and CEO of a publicly Listed Australian
Technology Development Company
CEO of a Specialty Chemicals company based in Canada CEO of Oregon, US based Biotech

10. Organize and manage meetings
for deal finalization
Advise on structuring the deal
Support in negotiations
(most critical)
Complete Agreement
Finalize
Broadcast Elevator Pitch/Teaser
by email to identified Relevant
Companies
Follow-up with phone calls and
emails
Coordinate CDAs with
interested Companies
Facilitate further discussions
and due diligence
Organize conference calls for
clarifications
Prospect
Capture important details about
your assets/technologies
Work with you to Finalize
‘Elevator Pitch (EP)/Teaser’
customized to specific business
culture
Identify relevant companies and
decision makers from our
relationships , and resources,
built and nurtured over 19+years
Based on mutually agreed
Criteria. Shortlist is used after
your review and approval
Setup
Aagami ‘s Proven Partnering Process
10
Up to 1 month 3 to 5 months 1 to 12+ months
All these steps require upto 80 hours of effort every month depending upon scope

11. 11
Engagement Model
• This ‘brings skin in the
game’ of both parties
• After 6 months you may
choose to continue based
on progress and your
experience with us
• One-time success fee
payment option also
available
• We get our profits only
from Success Bonus
• A team consisting Partner
level Consultant, Mid-
level Consultant, Analyst
is deployed
• Work with focus on your
success to get our bonus
Monthly Commitment Fee + Success Fee
Dedicated
Teamwork
Success bonus
Small Monthly
‘Commitment’
Fee
~80 hours/month/geography A small single digit % of
value received by you
for at least 6 months
We can also work on a simple hourly basis with no minimums.

12. Dinesh Jain
• Founder CEO, MBA
• Working since 1984
• Bio-Pharma clients –
Pieris, Phosphagenics,
Genentech, etc.
Michael
Rosen
Dr. Shridhar
Andurkar, Ph D. Nancy Chew
Dr. Aman Ahuja,
M.D., F.P.M., F.R.C.A.
Godwyn Francis
• Scientific Advisor
• Chair and Associate Prof. of
Pharmaceutical sciences
• Midwestern Univ., Chicago
College of Pharmacy
• Working since 1991
Aagami Leadership Team
• Partner, MBA
• Since 1974, Managed 3
MNC Pharma, Agritech,
• US, Europe, Latin
America, Japan & Israel
• Regulatory Expert
• Working since 1979
• A serial entrepreneur,
veteran business
leader, biochemist and
Pharmacologist
• Medical, Clinical
• Pain Specialist and
Anaesthetist uses
multidisciplinary
approach
• Practicing since 1998
• Vice President
• 20+ BioPharma
• Accenture, Prudential
plc, TATA, pManifold
• Working since 2000
Dr. Carlos Velez,
Ph D. MBA
• Partner
• Working since 1998
• CMTx , Lacerta, Connexin,
Panion, Ventac , Penwest,
Frankel
12
Akshay Bavaria
• Sr. Manager
• Business Development
and Consulting since
2013
250+ years of
cumulative experience

13. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Out-licensing of Transdermal Drug Delivery Technology
• To Out-License TPM® Technology and Co-Develop in clinic
products using proprietary Delivery technology and market
such products in India and possibly larger region.
13
TPM® Technology and Products Company from Australia
• Aagami scanned numerous companies and got 10 relevant
companies interested.
• Discussion with 8 companies progressed.
• Took client to India 3 times for term sheet level meetings
and deal signing.
• Facilitated entire evaluation and deal structuring process
• Aagami made sure testing and other protocols were
honoured before deal was made.
• During the process Aagami ensured clear understanding
despite socio cultural differences in styles of working.
• 4 Deals done with 3 global companies
– The first deal was for diclofenac topical gel formulation with
TPM. The Indian partner not only launched their own
product but also out licensed to a major western pharma.
Expanded to 16 more geographies worldwide in 2016.
– The second alliance was for use in Skin Whitening and
under eye cream.
– Third deal – The prospect using TPM increased bio
availability as well as stability of a specific antibiotic. Then
sold off that division for $1.6B

14. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Partnerships for Development and Commercialisation of
Novel Class of Protein Drugs
• The client wanted collaborative partners to develop novel
drugs in Oncology and Ophthalmology using their new class
of proteins - Anticalins®.
German Biotech company making differentiated Novel drugs
• Aagami identified right partners, and took them to 7
interested companies
• With focused efforts three companies moved to term sheet
level discussions. Two companies remained for final
negotiations.
• Aagami maintained its spirits and perseverance knowing
Indian ways of working; even when client was ready to give
up as per Western ways.
• Finally co-development partnership happened in next few
months with one company in Oncology and with another
company for ophthalmic therapy.
• Identifying right companies, advice on deal structure,
perseverance & commitment were the key success factors.
• Client signed co-development deals with 2 companies
in Oct and Dec 2013 respectively
• Aagami proved highly influential in negotiations for
finalization of the deals due to deep experience in
business culture nuances of India.
• The deals helped Pieris in their NASDAQ (PIRS) listing
in 2014, and also enabled higher valuation.
14

15. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
JV, Equity Investment & M&A on Milestone completion
• Investments/JV/M&A for further development of its
Biotechnologies and commercialization
15
Australia based company developing novel Biotechnologies with application in nutraceuticals
• Aagami identified right investors/ partners, and took them to
20 + companies.
• With focused efforts 3 companies had post CDA level
scientific and technical discussions.
• Aagami kept facilitating and persevering, 1 large company
moved to term sheet level discussions.
• Aagami travelled with client CEO to meet Chairman of
Strategic company in March 2020 to finalise the deal
• Supported client through structuring of the deal and
negotiations. Continued to support even after the term
sheet was signed, and until the definitive agreement was
completed in March 2021.
• Large Pharma, acquired 12.5% stake in WRS (March 2021)
with a provision to acquire over 50% on agreed milestone
completion.
• Based on the progress, the agreement has been signed for
100% acquisition.
Name of client partner is
CONFIDENTIAL

16. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Investment for development of therapeutic vaccines
• Investments and partnering to further develop its
technologies and pipeline.
16
Louisiana based biotechnology company specializing in innovative cancer treatments
• Aagami scanned the global market, identified right investors/
partners, and took them to 50 + companies.
• With focused efforts 10+ companies had post CDA level
scientific and clinical discussions.
• Aagami kept facilitating and persevering, 3 companies
moved to term sheet level discussions.
• Finally Aagami found a right partner to facilitate reverse
merger with a OTC Markets listed company.
• This is enabling access to large sums of funds to develop
clinical stage programs.
• Listing on OTC Markets by a reverse merger
• Financial resources to enable development of existing
pipeline and technologies

17. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Partnership for Anti Microbial Resistant Anti-infective Drug
• Find a suitable US partner to take FDA approvals and
market their AMR Anti-infective drug, to exploit full
market potential
17
Research Driven Publicly listed Indian Pharma Company
• Partnership established for Canada Market
• Term sheet signed for US market
— Aagami approached numerous companies and got 5
relevant companies interested.
— Discussion with 3 companies progressed to Due Diligence
levels.
— Aagami also represented the client in various Trade Shows
like BIO, J P Morgan, BIO Europe and Biotech Showcase;
resulting in interested companies from Canada, Europe,
Japan and Israel
— Facilitated entire evaluation and deal structuring process
with prospective companies
— During the process Aagami ensured clear understanding
despite socio cultural differences in styles of working.

18. 18
Some transactions did not further happen due to change in strategy by client/other reasons beyond Aagami control/Ongoing
discussions
Select Term Sheet level successes (Last 6 years only)
Client # of Term sheets & Year
Ingenio Inc.
1 (2022)
Ongoing
3 (2021)
2 (2021)
Ongoing
1 (2021)
Ongoing
1 (2021)
Ongoing
2 (2021)
1 (signed 2021)
Ongoing
2 (2020)
Ongoing
Client # of Term sheets & Year
2 (2019)
1 (2019)
3 (2018)
2 (2017)
2 (2017)
4 (2016)
2 (2016)
3 (2016)

19. 19
Few client opportunities we are presently working on:
1. Seeking Licensing/Co-development: Midwest US
based Pharma’s First-in-Class Non-Opioid
Analgesic for both chronic and acute Pain Relief.
2. Licensing/Strategic Partnership: Next-gen AI
powered imaging to pinpoint the IVF 24-hour
window of opportunity to implant the embryo.
First solution that supports the science of uterine
receptivity vs. a physician's estimates or
inaccurate ultrasound. Market Launch early 2024.
3. Licensing /Co-development - 505(b)(2) low cost
near market IP protected Bendamustine.
Negligible competition(3) in the ~$500M US
market. Good market share potential. US Market
Launch ~Mid 2024
For Licensing/Partnering/Co-development:
4. Available for licensing: Phase I asset for
Moderate-Severe Pain; Fast Track
designation; Clinical Study on-going.
5. Available for licensing: Transdermal
smart patch asset with Proprietary
technology for Alzheimer’s Disease; IND
filing in progress. Safer and non-
irritable.
6. Technology Licensing: Easy to apply
Microneedle Array Patch (MAP) system
to deliver drugs, vaccines; better
immune response than injection. A
painless and efficient replacement to
Syringes.

20. 20
Few client opportunities we are presently working on:
1. Mountain View Pharma (MVP) and its PharmaPEG® technology, product candidates, data, & IP
package - for Next-generation biologics and substantial returns. Available at a very reasonable price.
For Acquisition
1. $40 Million Series C Open: US FDA approved portable MRI Guided Treatment, Diagnosis and
Screening, for Urology applications. Extended Series B available for a very limited time.
2. Series A $25M Financing: Midwest US based Pharma First-in-Class Non-Opioid Analgesic for Pain
Relief. Just $3.5 Million needed to complete next milestone.
3. Seeking $10 Million Series A– for FDA clearance and go-to-market. First in class AI assisted
hysteroscopy for doubling the success rate in IVF implantation. Pinpoints a 24-hour window of
opportunity to implant the embryo. First solution that supports the science of uterine receptivity
vs. a physician's estimates or inaccurate ultrasound. Market Launch early 2024.
Investment Opportunities

21. Offerings in Market Intelligence/Business Research
Competitive
Landscape
Assessments
Analysis of
Portfolio
Opportunities
identification
Price Discovery
Research
Due Diligence
IP and Regulatory
Research
Financial
Modeling, NPV
valuations
New Market Entry
strategy
Market
development
strategy
21

22. Aagami, Inc.
2020 Calamos Court, Suite 200
Naperville, IL 60653, USA
+1-630-364-1837
Business Development
Godwyn Francis, Vice President
godwyn@aagami.com
M: +1 630-909-3341
www.aagami.com 22
CONTACT US